Regeneron and Avalanche Biotechnologies Announce Collaboration to Develop Next-Generation Gene Therapy Products in Ophthalmology Regeneron Pharmaceuticals, Inc. and Avalanche Biotechnologies, Inc. announced the formation of a broad collaboration to discover, develop and commercialize novel gene therapy products for the treatment of ophthalmologic diseases. Under the terms of the agreement, Avalanche will receive an upfront cash payment, contingent payments of up to $640 million upon achievement of certain development and regulatory milestones, plus a royalty on worldwide net sales of collaboration products. [Regeneron Pharmaceuticals, Inc.] Press Release NeoStem’s Subsidiary, Progenitor Cell Therapy, Enters into a Services Agreement with IRX Therapeutics, Inc. NeoStem, Inc. and its subsidiary, Progenitor Cell Therapy, LLC (PCT), announced the execution of a Services Agreement with IRX Therapeutics, Inc. (IRX) under which PCT will provide services to support IRX’s development of IRX-2, a primary cell-derived biologic with multiple active cytokine components. IRX-2 is a cancer therapeutic designed to activate a patient’s immune system to broadly restore immunity and overcome cancer-induced immune suppression. [NeoStem, Inc.] Press Release CRISPR Therapeutics Raises $25 Million in Series A Financing and Announces Founding Team of World-Renowned Academics and Clinicians CRISPR Therapeutics has raised $25 million in a series A investment from Versant Ventures. The company announced a founding team comprising high-profile experts in diverse fields of science including CRISPR-Cas9, genome editing, stem cell biology, advanced drug delivery technologies, RNA interference and gene silencing. [Business Wire] Press Release UGA to Use $5 Million Gift to Support Center for Molecular Medicine A $5 million gift to support the Center for Molecular Medicine at the University of Georgia (UGA) will allow the institution to greatly advance its research into human disease. [University of Georgia] Press Release Pluristem Awarded $4.2 Million Grant by Israeli Government Pluristem Therapeutics Inc. announced that its wholly owned subsidiary, Pluristem Ltd., has received approval for a 14.6 million New Israeli Shekel (approximately $4.2 million) grant from the Office of the Chief Scientist within the Israeli Ministry of Economy. [Pluristem Therapeutics Inc.] Press Release Aduro BioTech Announces Initiation of a Clinical Trial of Its Novel Immunotherapy in Patients with Brain Cancer at Providence Cancer Center Aduro BioTech, Inc. announced that the first patients have been enrolled in a Phase I clinical trial to evaluate its novel immunotherapy ADU-623 in patients with high-grade glioma, a form of brain cancer. [Business Wire] Press Release Mesoblast Provides Update on Clinical Programs of Prochymal® for Crohn’s Disease and Acute Graft versus Host Disease Mesoblast Limited provided an update on its clinical programs using the product Prochymal®, which was acquired as part of the entire culture-expanded mesenchymal stem cell business of Osiris Therapeutics by the Mesoblast Group. [Mesoblast Limited] Download Press Release IntelliCell BioSciences’ Stromal Vascular Cell Technology Used for Restorative Cardiac Function with Dr. Zain Khalpey IntelliCell BioSciences, Inc. announced that it supplied its Stromal Vascular Fraction Cells, manufactured using its patented ultrasonic technology, for the restoration of cardiac function at the University of Arizona College of Medicine, Tucson in collaboration with Dr. Zain Khalpey, Division of Cardiothoracic Surgery. [PR Newswire Association LLC] Press Release WuXi PharmaTech Breaks Ground on New Cell Therapy Manufacturing Facility WuXi PharmaTech (Cayman) Inc. announced that it has broken ground on a new facility in Philadelphia for the manufacture of cell therapies. The facility is expected to become operational in the second quarter of 2015. [WuXi PharmaTech (Cayman) Inc.] Press Release C. Randal Mills Named as New President of California’s Stem Cell Agency The California Institute for Regenerative Medicine appointed C. Randal Mills, Ph.D., as its new President and Chief Executive Officer. Mills, the former President and CEO of Osiris Therapeutics, was selected by the agency’s governing Board, the Independent Citizens Oversight Committee. [California Institute for Regenerative Medicine] Press Release |